It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hotspot mutations in the PEST-domain of NOTCH1 and NOTCH2 are recurrently identified in B cell malignancies. To address how NOTCH-mutations contribute to a dismal prognosis, we have generated isogenic primary human tumor cells from patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), differing only in their expression of the intracellular domain (ICD) of NOTCH1 or NOTCH2. Our data demonstrate that both NOTCH-paralogs facilitate immune-escape of malignant B cells by up-regulating PD-L1, partly dependent on autocrine interferon-γ signaling. In addition, NOTCH-activation causes silencing of the entire HLA-class II locus via epigenetic regulation of the transcriptional co-activator CIITA. Notably, while NOTCH1 and NOTCH2 govern similar transcriptional programs, disease-specific differences in their expression levels can favor paralog-specific selection. Importantly, NOTCH-ICD also strongly down-regulates the expression of CD19, possibly limiting the effectiveness of immune-therapies. These NOTCH-mediated immune escape mechanisms are associated with the expansion of exhausted CD8+ T cells in vivo.
NOTCH mutations are frequent in B cell malignancies. Here the authors use retroviral transduction of primary malignant B cells from Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) patients to show that NOTCH1/2-mutations facilitate mechanism of immune escape.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Charalampopoulou, Stella 2 ; Gerhard-Hartmann, Elena 3 ; Bloehdorn, Johannes 4
; Moore, Andrew 1
; Giachetti, Giorgia 1 ; Lu, Junyan 5
; Roamio Franklin, Valar Nila 6 ; Chilamakuri, Chandra Sekkar Reddy 6 ; Moutsopoulos, Ilias 7
; Rosenwald, Andreas 3 ; Stilgenbauer, Stephan 4 ; Zenz, Thorsten 8
; Mohorianu, Irina 7 ; D’Santos, Clive 6 ; Deaglio, Silvia 9
; Hodson, Daniel J. 1
; Martin-Subero, Jose I. 10
; Ringshausen, Ingo 1
1 University of Cambridge, Wellcome/MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge, Department of Haematology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
2 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (GRID:grid.10403.36) (ISNI:0000000091771775)
3 Pathologisches Institut Universität Würzburg, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)
4 Ulm University, Department of Internal Medicine III, Division of CLL, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
5 European Molecular Biology Laboratory (EMBL), Heidelberg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X); Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany (GRID:grid.4709.a)
6 University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
7 University of Cambridge, Wellcome/MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
8 University Hospital Zürich and University of Zürich, Department of Medical Oncology and Hematology, Zürich, Switzerland (GRID:grid.412004.3) (ISNI:0000 0004 0478 9977); National Center for Tumor Diseases and German Cancer, Research Centre, Molecular Therapy in Hematology and Oncology, Heidelberg, Germany (GRID:grid.461742.2) (ISNI:0000 0000 8855 0365)
9 University of Turin, Department of Medical Sciences, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
10 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (GRID:grid.10403.36) (ISNI:0000000091771775); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (GRID:grid.425902.8) (ISNI:0000 0000 9601 989X)




